New cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT07100067
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new cell therapy called LCAR-F33S in 35 people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to attack the cancer. The main goals are to check safety, find the right dose, and see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LCAR-F33S cells (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is a very early, small study (35 people) focused on safety and dosing. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Boren Hospital
NOT_YET_RECRUITINGBeijing, China
Contact Email: •••••@•••••
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Wuhan Union Hospital
RECRUITINGWuhan, China
Contact Email: •••••@•••••